AI and Sequential Organ Failure Assessment
Peach IntelliHealth is a New York based Artificial Intelligence & Machine Learning (AI/ML) healthcare company. Founded by five MIT scientists, their product Peach ACE is used to predict patient trajectory hours before measurable signals. The company was founded in 2013 and has yet to take a major funding round, though it is currently seeking synergistic partners. Peach IntelliHealth recently filed their first patent application for their technology, which could point to a desire to increase valuation in order to bring in capital to scale.
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…